Another EGFR/CD3/HSA trispecific construct named tumor-activated T cell engager (TRACTr) 97 contains two protease cleavable masks that inhibit both EGFR binding on target cells and CD3 engagement on T cells. Here, EGFR is linked to neoplasm.